Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-009 in surgically-refractory epilepsy
NCT03646240Phase 1Completed
- Sponsor
- Seattle Children's
- Start
- Jul 2018
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-sirolimus in epilepsy, sponsored by Seattle Children's. Primary endpoint: Maximum tolerated dose at 3 weeks. Started Jul 2018; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03646240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646240.